Craig-Hallum analyst Chase Knickerbocker lowered the firm’s price target on PolyPid (PYPD) to $13 from $15 and keeps a Buy rating on the shares following quarterly results. The biggest highlight of the quarter was the positive Shield 2 data and the following warrant inducement providing $27M and extending the cash runway into the second half of 2026, allowing them to pursue a partnership for U.S. rights to D-Plex100, with active discussions ongoing, the firm says. A development milestone from the Advanz partnership in the EU may also be coming up, Craig-Hallum adds.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PYPD:
- PolyPid price target raised to $10 from $9 at Roth Capital
- PolyPid Reports Strong Phase 3 Results and Financial Update
- PolyPid Releases Mid-2025 Financial Update
- PolyPid’s Promising Outlook: Buy Rating Affirmed Amidst Positive Phase 3 Results and Strategic Advancements
- PolyPid Reports Positive Phase 3 Results and Strengthens Leadership